SFPQ

Summary

SFPQ (splicing factor proline and glutamine rich, HGNC:10774) is a protein-coding gene on chromosome 1p34.3, encoding Splicing factor, proline- and glutamine-rich (P23246). DNA- and RNA binding protein, involved in several nuclear processes. It is a common-essential gene (DepMap: required in 99.9% of cancer cell lines).

Enables DNA binding activity; histone deacetylase binding activity; and protein homodimerization activity. Involved in several processes, including alternative mRNA splicing, via spliceosome; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway; and regulation of transcription by RNA polymerase II. Acts upstream of or within double-strand break repair via homologous recombination. Located in chromatin; nuclear matrix; and paraspeckles.

Source: NCBI Gene 6421 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 70 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 99.9% of screened cell lines (common-essential)
• Transcription factor: yes — 30 downstream targets (CollecTRI)
• MANE Select transcript: NM_005066

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10774
Approved symbol	SFPQ
Name	splicing factor proline and glutamine rich
Location	1p34.3
Locus type	gene with protein product
Status	Approved
Aliases	PSF, PPP1R140
Ensembl gene	ENSG00000116560
Ensembl biotype	protein_coding
OMIM	605199
Entrez	6421

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding_CDS_not_defined, 2 protein_coding, 2 nonsense_mediated_decay

ENST00000357214, ENST00000460428, ENST00000466213, ENST00000466745, ENST00000468598, ENST00000470472, ENST00000471991, ENST00000485365, ENST00000485454, ENST00000490668, ENST00000696553

RefSeq mRNA: 1 — MANE Select: NM_005066 NM_005066

CCDS: CCDS388

Canonical transcript exons

ENST00000357214 — 10 exons

Exon	Start	End
ENSE00000956026	35191341	35191529
ENSE00000956027	35190694	35190995
ENSE00000956028	35190498	35190593
ENSE00000956029	35189186	35189382
ENSE00000956030	35189003	35189087
ENSE00000956031	35187973	35188090
ENSE00000956032	35187203	35187251
ENSE00000956033	35187001	35187122
ENSE00001460205	35182936	35184593
ENSE00001460236	35192222	35193145

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 377.1436 / max 3121.3761, expressed in 1828 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11672	368.2795	1828
11668	3.3119	1296
11667	1.9981	994
11670	1.3679	764
11666	0.9691	545
11669	0.9279	522
11662	0.2893	133

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	99.65	gold quality
tendon of biceps brachii	UBERON:0008188	99.65	gold quality
ganglionic eminence	UBERON:0004023	99.61	gold quality
right uterine tube	UBERON:0001302	99.57	gold quality
sural nerve	UBERON:0015488	99.53	gold quality
cerebellar hemisphere	UBERON:0002245	99.52	gold quality
cortical plate	UBERON:0005343	99.50	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.50	gold quality
left ovary	UBERON:0002119	99.47	gold quality
cerebellar cortex	UBERON:0002129	99.46	gold quality
tibial nerve	UBERON:0001323	99.45	gold quality
right ovary	UBERON:0002118	99.45	gold quality
sperm	CL:0000019	99.41	gold quality
right testis	UBERON:0004534	99.38	gold quality
skin of abdomen	UBERON:0001416	99.37	gold quality
skin of leg	UBERON:0001511	99.37	gold quality
endocervix	UBERON:0000458	99.36	gold quality
calcaneal tendon	UBERON:0003701	99.36	gold quality
left testis	UBERON:0004533	99.34	gold quality
body of uterus	UBERON:0009853	99.34	gold quality
tendon	UBERON:0000043	99.33	gold quality
ovary	UBERON:0000992	99.33	gold quality
embryo	UBERON:0000922	99.32	gold quality
cerebellum	UBERON:0002037	99.32	gold quality
right lobe of thyroid gland	UBERON:0001119	99.30	gold quality
metanephros cortex	UBERON:0010533	99.30	gold quality
left uterine tube	UBERON:0001303	99.29	gold quality
adenohypophysis	UBERON:0002196	99.29	gold quality
left lobe of thyroid gland	UBERON:0001120	99.28	gold quality
male germ cell	CL:0000015	99.27	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-13	yes	19.86
E-CURD-135	no	1019.62
E-CURD-79	no	874.47
E-GEOD-93593	no	7.05
E-ANND-3	no	0.00

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

30 targets.

Target	Regulation
ACTB
ADARB2	Repression
AIFM1	Repression
AR
CTBP1
CXCL8	Repression
CYP11A1
CYP17A1
CYP2B6
DNAAF4	Unknown
EPHX1
GJA1
HDAC2	Unknown
HSPA9
IGF1
NEAT1	Unknown
NR3C1	Unknown
PER1
PGR	Repression
PPARGC1A	Repression
PRL
PTGS2	Unknown
PTPRC	Repression
RBP4
SIN3A
SMC3
SP1
STAT6	Repression
TH	Unknown
TOP2B

Upstream regulators (CollecTRI, top): E2F4

miRNA regulators (miRDB)

110 targeting SFPQ, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3662	99.99	73.82	5684
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-548AE-3P	99.93	72.66	4867

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 99.9% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• Here we show that PSF interacts with p54nrb.PSF bind U5 snRNA with both the sequence and structure of stem 1b contributing to binding specificity. (PMID:12403470)
• Review article of PSF as a multi-functional nuclear protein. (PMID:12417296)
• p54nrb and PSF have properties of key factors mediating INS function and likely define a novel mRNA regulatory pathway that is hijacked by HIV-1. (PMID:12944487)
• The PSF.p54(nrb) complex cooperates with Ku protein to form a functional preligation complex with substrate DNA (PMID:15590677)
• Data suggest that polypyrimidine tract-binding protein-associated splicing factor acts as a progesterone receptor corepressor and contributes to the functional withdrawal of progesterone and the initiation of human labor. (PMID:15668243)
• recruitment of PSF to activated promoters and the carboxyl-terminal domain of RNA polymerase II provides a mechanism by which transcription and pre-mRNA processing are coordinated within the cell. (PMID:16024807)
• DJ-1 transcriptionally up-regulates the human tyrosine hydroxylase by inhibiting the sumoylation of pyrimidine tract-binding protein-associated splicing factor (PMID:16731528)
• Expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary renal cell carcinomas (PMID:16832349)
• Mass spectrometric analysis of the complex revealed the polypyrimidine tract-binding protein-associated splicing factor (PSF) as a novel Hepatitis Delta virus RNA-interacting protein. (PMID:16938326)
• These results suggest that IbeA interacts with polypyrimidine tract-binding protein (PTB)-associated splicing factor (PSF) for the E. coli K1 invasion of HBMEC.[IbeA] (PMID:17318576)
• These data demonstrated that PSF and p54nrb complex with AR and play a key role in modulating AR-mediated gene transcription. (PMID:17452459)
• Identification of PSF, p54(nrb), PTB, and U1A as proteins specifically bound to the COX-2 polyadenylation signal upstream sequence elements . (PMID:17507659)
• identify PSF as a novel nucleophosmin 1/anaplastic lymphoma kinase-binding protein and substrate (PMID:17537995)
• XRN2 associates with p54nrb/NonO(p54)-protein-associated splicing factor (PSF), multifunctional proteins involved in several nuclear processes. (PMID:17639083)
• Findings suggest that the PSF.p54nrb complex is a novel MAP kinase signal-integrating kinases substrate that binds the mRNA for tumor necrosis factor alpha. (PMID:17965020)
• TFII-I, PARP1, and SFPQ proteins, each previously implicated in gene regulation, form a complex controlling transcription of DYX1C1. Allelic differences in the promoter or 5’UTR of DYX1C1 may affect factor binding and thus regulation of the gene. (PMID:18445785)
• Co-expression of PSF relocates oncogenic RING finger protein 43 (RNF43) from the nuclear periphery to the nucleoplasm. (PMID:18655028)
• These findings are suggestive of a role for myometrial PSF as a nuclear co-regulator in the regulation of specific hormone receptor genes and their target hormone response genes. (PMID:19339282)
• results suggest that PSF may have dual functions in homologous recombination and RNA processing through its N-terminal and central regions, respectively. (PMID:19447914)
• Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. (PMID:19809274)
• Disruption of the growth hormone receptor polypyrimidine tract causes aberrant mRNA splicing resulting in growth hormone insensitivity. (PMID:19812236)
• PSF (polypyrimidine tract-binding protein-associated splicing factor) and p54(nrb), two highly related proteins involved in transcription and RNA processing, are identified as new binding partners of hnRNP M. (PMID:19874820)
• SFPQ/NONO heterodimer is involved in the early stage of the DSB response. (PMID:20421735)
• In response to hyperosmotic stress, p38 also regulates formation of complexes between hDlg and PSF. (PMID:20605917)
• GSK3/TRAP150, complex regulates CD45 alternative splicing and demonstrate a paradigm for signal transduction from the cell surface to the RNA processing machinery through the multifunctional protein PSF. (PMID:20932480)
• these results identify PSF as a repressor of STAT6-mediated transcription that functions through recruitment of HDAC to the STAT6 transcription complex, and delineates a novel regulatory mechanism of IL-4 signaling (PMID:21106524)
• PSF influences repair via direct, local, interaction with the DNA substrate (PMID:21144806)
• RVxF motifs play an important role in controlling the multifunctional properties of p54nrb and PSF in the regulation of gene transcription (PMID:21566083)
• Data reveal a new player in tau exon 10 alternative splicing regulation and uncover a previously unknown mechanism of PSF in regulating tau pre-mRNA splicing. (PMID:21881826)
• results indicate that SFPQ/PSF is a host factor essential for influenza virus transcription that increases the efficiency of viral mRNA polyadenylation (PMID:22114566)
• The results suggested that PSF may function as an activator for the meiosis-specific recombinase DMC1. (PMID:22156371)
• Localisation of TopBP1 at DNA damage sites was noticed as early as 5 s following damage induction, whereas p54(nrb) and PSF localised there after 20 s. (PMID:22213094)
• In Alzheimer’s disease, Pick’s disease, and Frontotemporal Lobar Degeneration Tau-mediates nuclear depletion and cytoplasmic accumulation of SFPQ. (PMID:22558197)
• Partial knockdown of Annexin A2 and PSF showed decrease in p53 IRES activity and reduced levels of both the p53 isoforms. (PMID:23131771)
• PSF and MATR3 are cellular host factors that bind viral RNA and promote Rev activity. (PMID:23158102)
• the effects of PSF on cell proliferation, tumor growth, and cell signaling associated with PPARgamma (PMID:23516550)
• Results suggest that Llme23 can function as an oncogenic RNA and directly associate the polypyrimidine tract-binding (PTB) protein-associated splicing factor (PSF)-binding lncRNA with melanoma. (PMID:23618401)
• The results of this study identify a new physiological role for the PSF-LC3B axis as a potential endogenous modulator of colon cancer treatment. (PMID:24288667)
• NEAT1 plays an important role in the innate immune response through the transcriptional regulation of antiviral genes by the stimulus-responsive cooperative action of NEAT1 and SFPQ. (PMID:24507715)
• MALAT1 binds to SFPQ releasing PTBP2 from the SFPQ/PTBP2 complex, the increased SFPQ-detached PTBP2 promotes cell proliferation and migration in colorectal cancer. (PMID:25025966)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	sfpq	ENSDARG00000011564
mus_musculus	Sfpq	ENSMUSG00000028820
rattus_norvegicus	Sfpq	ENSRNOG00000058461
drosophila_melanogaster	nonA	FBGN0004227
drosophila_melanogaster	nonA-l	FBGN0015520
drosophila_melanogaster	nito	FBGN0027548
caenorhabditis_elegans		WBGENE00017778

Paralogs (7): SPEN (ENSG00000065526), PSPC1 (ENSG00000121390), NONO (ENSG00000147140), RAVER1 (ENSG00000161847), RAVER2 (ENSG00000162437), RBM15 (ENSG00000162775), RBM15B (ENSG00000259956)

Protein

Protein identifiers

Splicing factor, proline- and glutamine-rich — P23246 (reviewed: P23246)

Alternative names: 100 kDa DNA-pairing protein, DNA-binding p52/p100 complex, 100 kDa subunit, Polypyrimidine tract-binding protein-associated-splicing factor

All UniProt accessions (5): P23246, A0A384N5Z8, A0A8Q3WMA7, H0Y9K7, H0Y9U2

UniProt curated annotations — full annotation on UniProt →

Function. DNA- and RNA binding protein, involved in several nuclear processes. Essential pre-mRNA splicing factor required early in spliceosome formation and for splicing catalytic step II, probably as a heteromer with NONO. Binds to pre-mRNA in spliceosome C complex, and specifically binds to intronic polypyrimidine tracts. Involved in regulation of signal-induced alternative splicing. During splicing of PTPRC/CD45, a phosphorylated form is sequestered by THRAP3 from the pre-mRNA in resting T-cells; T-cell activation and subsequent reduced phosphorylation is proposed to lead to release from THRAP3 allowing binding to pre-mRNA splicing regulatotry elements which represses exon inclusion. Interacts with U5 snRNA, probably by binding to a purine-rich sequence located on the 3’ side of U5 snRNA stem 1b. May be involved in a pre-mRNA coupled splicing and polyadenylation process as component of a snRNP-free complex with SNRPA/U1A. The SFPQ-NONO heteromer associated with MATR3 may play a role in nuclear retention of defective RNAs. SFPQ may be involved in homologous DNA pairing; in vitro, promotes the invasion of ssDNA between a duplex DNA and produces a D-loop formation. The SFPQ-NONO heteromer may be involved in DNA unwinding by modulating the function of topoisomerase I/TOP1; in vitro, stimulates dissociation of TOP1 from DNA after cleavage and enhances its jumping between separate DNA helices. The SFPQ-NONO heteromer binds DNA. The SFPQ-NONO heteromer may be involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination and may stabilize paired DNA ends; in vitro, the complex strongly stimulates DNA end joining, binds directly to the DNA substrates and cooperates with the Ku70/G22P1-Ku80/XRCC5 (Ku) dimer to establish a functional preligation complex. SFPQ is involved in transcriptional regulation. Functions as a transcriptional activator. Transcriptional repression is mediated by an interaction of SFPQ with SIN3A and subsequent recruitment of histone deacetylases (HDACs). The SFPQ-NONO-NR5A1 complex binds to the CYP17 promoter and regulates basal and cAMP-dependent transcriptional activity. SFPQ isoform Long binds to the DNA binding domains (DBD) of nuclear hormone receptors, like RXRA and probably THRA, and acts as a transcriptional corepressor in absence of hormone ligands. Binds the DNA sequence 5’-CTGAGTC-3’ in the insulin-like growth factor response element (IGFRE) and inhibits IGF1-stimulated transcriptional activity. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-BMAL1 heterodimer. Required for the transcriptional repression of circadian target genes, such as PER1, mediated by the large PER complex through histone deacetylation. Required for the assembly of nuclear speckles. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway.

Subunit / interactions. Heterodimer with NONO. Monomer and component of the SFPQ-NONO complex, which is probably a heterotetramer of two 52 kDa (NONO) and two 100 kDa (SFPQ) subunits. The coiled coil domain mediates interaction with NONO, and can also mediate formation of long, linear homooligomers (in vitro). SFPQ is a component of spliceosome and U5.4/6 snRNP complexes. Interacts with SNRPA/U1A. Component of a snRNP-free complex with SNRPA/U1A. Part of complex consisting of SFPQ, NONO and MATR3. Interacts with polypyrimidine tract-binding protein 1/PTB. Part of a complex consisting of SFPQ, NONO and NR5A1. Interacts with RXRA, probably THRA, and SIN3A. Interacts with TOP1. Part of a complex consisting of SFPQ, NONO and TOP1. Interacts with SNRNP70 in apoptotic cells. Interacts with PSPC1. Interacts with RNF43. Interacts with PITX3 and NR4A2/NURR1. Interacts with PTK6. Interacts with THRAP3; the interaction is dependent on SFPQ phosphorylation at ‘Thr-687’ and inhibits binding of SFPQ to a ESS1 exonic splicing silencer element-containing RNA. The large PER complex involved in the histone deacetylation is composed of at least HDAC1, PER2, SFPQ and SIN3A. Interacts with PER1 and PER2. Interacts with PQBP1. Component of a multiprotein complex with NONO and WASL. Interacts with ERCC6. (Microbial infection) Interacts with M.tuberculosis protein Rv3654c, which probably leads to the cleavage of PSF, diminishes the level of caspase-8 in macrophages and suppresses macrophage apoptosis by blocking the extrinsic pathway. Part of the HDP-RNP complex composed of at least HEXIM1, PRKDC, XRCC5, XRCC6, paraspeckle proteins (SFPQ, NONO, PSPC1, RBM14, and MATR3) and NEAT1 RNA.

Subcellular location. Nucleus speckle. Nucleus matrix. Cytoplasm.

Post-translational modifications. The N-terminus is blocked. Phosphorylated on multiple serine and threonine residues during apoptosis. In vitro phosphorylated by PKC. Phosphorylation stimulates binding to DNA and D-loop formation, but inhibits binding to RNA. Phosphorylation of C-terminal tyrosines promotes its cytoplasmic localization, impaired its binding to polypyrimidine RNA and led to cell cycle arrest. In resting T-cells is phosphorylated at Thr-687 by GSK3B which is proposed to promote association with THRAP and to prevent binding to PTPRC/CD45 pre-mRNA; T-cell activation leads to reduced phosphorylation at Thr-687.

Disease relevance. A chromosomal aberration involving SFPQ may be a cause of papillary renal cell carcinoma (PRCC). Translocation t(X;1)(p11.2;p34) with TFE3.

Domain organisation. The coiled coil domain mediates interaction with NONO, and can also mediate formation of long, linear homooligomers (in vitro). The coiled coil domain is required for optimal DNA binding, and optimal transcription activation.

Isoforms (2)

UniProt ID	Names	Canonical?
P23246-1	Long, A	yes
P23246-2	Short, F

RefSeq proteins (1): NP_005057* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000504	RRM_dom	Domain
IPR012677	Nucleotide-bd_a/b_plait_sf	Homologous_superfamily
IPR012975	NOPS	Domain
IPR034525	PSF_RRM1	Domain
IPR034526	PSF_NOPS	Domain
IPR035979	RBD_domain_sf	Homologous_superfamily

Pfam: PF00076, PF08075

UniProt features (92 total): modified residue 28, strand 16, helix 12, compositionally biased region 10, mutagenesis site 6, turn 4, repeat 3, cross-link 3, region of interest 3, domain 2, chain 1, site 1, splice variant 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
7LRU	X-RAY DIFFRACTION	1.6
7SP0	X-RAY DIFFRACTION	1.83
6NCQ	X-RAY DIFFRACTION	1.9
6OWJ	X-RAY DIFFRACTION	1.94
4WII	X-RAY DIFFRACTION	2.05
5WPA	X-RAY DIFFRACTION	2.29
7LRQ	X-RAY DIFFRACTION	2.3
7UK1	X-RAY DIFFRACTION	2.7
6WMZ	X-RAY DIFFRACTION	2.85
7PU5	X-RAY DIFFRACTION	3
4WIK	X-RAY DIFFRACTION	3
4WIJ	X-RAY DIFFRACTION	3.49
7UJ1	X-RAY DIFFRACTION	3.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23246-F1	69.79	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 662–663 (breakpoint for translocation to form sfpq-tfe3)

Post-translational modifications (31): 8, 9, 9, 33, 208, 236, 242, 245, 273, 283, 293, 314, 319, 338, 368, 374, 379, 421, 472, 496 …

Mutagenesis-validated functional residues (6):

Position	Phenotype
535	impairs dna binding and ability to mediate transcriptional activation; when associated with a-539; a-546 and a-549.
539	impairs dna binding and ability to mediate transcriptional activation; when associated with a-535; a-546 and a-549.
546	impairs dna binding and ability to mediate transcriptional activation; when associated with a-535; a-539 and a-549.
549	impairs dna binding and ability to mediate transcriptional activation; when associated with a-535; a-539 and a-546.
687	abolishes phosphorylation by gsk3b. impairs interaction with thrap3.
687	no effect on interaction with thrap3 (phosphomimetic).

Function

Pathways and Gene Ontology

Reactome pathways

10 pathways

ID	Pathway
R-HSA-8849468	PTK6 Regulates Proteins Involved in RNA Processing
R-HSA-9635465	Suppression of apoptosis
R-HSA-162582	Signal Transduction
R-HSA-1643685	Disease
R-HSA-5663205	Infectious disease
R-HSA-8848021	Signaling by PTK6
R-HSA-9006927	Signaling by Non-Receptor Tyrosine Kinases
R-HSA-9635486	Infection with Mycobacterium tuberculosis
R-HSA-9637690	Response of Mtb to phagocytosis
R-HSA-9824439	Bacterial Infection Pathways

MSigDB gene sets: 397 (showing top): GOBP_CIRCADIAN_RHYTHM, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_CHROMOSOME_ORGANIZATION, WANG_CLIM2_TARGETS_UP, GOBP_AXO_DENDRITIC_TRANSPORT, BROWNE_HCMV_INFECTION_8HR_UP, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, DITTMER_PTHLH_TARGETS_UP, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, DARWICHE_SKIN_TUMOR_PROMOTER_DN, DARWICHE_PAPILLOMA_RISK_LOW_UP, DARWICHE_PAPILLOMA_RISK_HIGH_UP, DARWICHE_SQUAMOUS_CELL_CARCINOMA_UP, GNF2_MCM5, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION

GO Biological Process (23): negative regulation of transcription by RNA polymerase II (GO:0000122), alternative mRNA splicing, via spliceosome (GO:0000380), double-strand break repair via homologous recombination (GO:0000724), activation of innate immune response (GO:0002218), chromatin remodeling (GO:0006338), regulation of DNA-templated transcription (GO:0006355), mRNA processing (GO:0006397), RNA splicing (GO:0008380), regulation of circadian rhythm (GO:0042752), negative regulation of circadian rhythm (GO:0042754), innate immune response (GO:0045087), positive regulation of sister chromatid cohesion (GO:0045876), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), rhythmic process (GO:0048511), chromosome organization (GO:0051276), dendritic transport of messenger ribonucleoprotein complex (GO:0098963), positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902177), immune system process (GO:0002376), DNA repair (GO:0006281), DNA recombination (GO:0006310), DNA damage response (GO:0006974), regulation of cell cycle (GO:0051726)

GO Molecular Function (8): transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), chromatin binding (GO:0003682), RNA binding (GO:0003723), protein homodimerization activity (GO:0042803), histone deacetylase binding (GO:0042826), nucleic acid binding (GO:0003676), protein binding (GO:0005515)

GO Cellular Component (10): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear matrix (GO:0016363), nuclear speck (GO:0016607), dendrite (GO:0030425), paraspeckles (GO:0042382), RNA polymerase II transcription regulator complex (GO:0090575), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Signaling by PTK6	1
Response of Mtb to phagocytosis	1
Disease	1
Signaling by Non-Receptor Tyrosine Kinases	1
Signal Transduction	1
Bacterial Infection Pathways	1
Infection with Mycobacterium tuberculosis	1
Infectious disease	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	5
binding	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
DNA-templated transcription	2
RNA processing	2
circadian rhythm	2
biological_process	2
nucleic acid binding	2
nuclear lumen	2
nuclear ribonucleoprotein granule	2
negative regulation of DNA-templated transcription	1
mRNA splicing, via spliceosome	1
recombinational repair	1
double-strand break repair	1
activation of immune response	1
positive regulation of innate immune response	1
chromatin organization	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
mRNA metabolic process	1
regulation of biological process	1
regulation of circadian rhythm	1
negative regulation of biological process	1
immune response	1
defense response to symbiont	1
sister chromatid cohesion	1
regulation of sister chromatid cohesion	1
positive regulation of cell cycle process	1
positive regulation of chromosome organization	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
organelle organization	1
dendritic transport	1
intrinsic apoptotic signaling pathway in response to oxidative stress	1
regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	1
positive regulation of intrinsic apoptotic signaling pathway	1
DNA metabolic process	1
DNA damage response	1

Protein interactions and networks

STRING

2272 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SFPQ	RBM14	Q96PK6	993
SFPQ	A0A0A6YYI9	A0A0A6YYI9	992
SFPQ	PTBP2	Q9UKA9	989
SFPQ	NONO	P30807	983
SFPQ	PSPC1	Q8WXF1	982
SFPQ	MATR3	P43243	954
SFPQ	FUS	P35637	933
SFPQ	TFE3	P19532	873
SFPQ	ASPSCR1	Q9BZE9	824
SFPQ	HNRNPM	P52272	823
SFPQ	PRCC	Q92733	812
SFPQ	HNRNPC	P07910	759
SFPQ	SIN3A	Q96ST3	743
SFPQ	U2AF1	Q01081	724
SFPQ	HNRNPU	Q00839	721

IntAct

300 interactions, top by confidence:

A	B	Type	Score
NONO	SFPQ	psi-mi:“MI:0915”(physical association)	0.900
SFPQ	NONO	psi-mi:“MI:2364”(proximity)	0.900
NONO	SFPQ	psi-mi:“MI:0914”(association)	0.900
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SFPQ	PSPC1	psi-mi:“MI:0403”(colocalization)	0.700
PTBP1	SFPQ	psi-mi:“MI:0915”(physical association)	0.700
SFPQ	PSPC1	psi-mi:“MI:0915”(physical association)	0.700
SFPQ	FMR1	psi-mi:“MI:0915”(physical association)	0.670
HIP1R	HIP1	psi-mi:“MI:0914”(association)	0.640
FAM98A	HERC2	psi-mi:“MI:0914”(association)	0.640
NCBP2	KPNA3	psi-mi:“MI:0914”(association)	0.640
CHEK2	PPM1G	psi-mi:“MI:0914”(association)	0.560
GAS7	SFPQ	psi-mi:“MI:0914”(association)	0.560
RNF43	SFPQ	psi-mi:“MI:0915”(physical association)	0.560
RNF43	SFPQ	psi-mi:“MI:0403”(colocalization)	0.560
SFPQ	FXR1	psi-mi:“MI:0915”(physical association)	0.550
SYNGAP1	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
NONO	SERPINB7	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480

BioGRID (824): SFPQ (Affinity Capture-Western), SFPQ (Affinity Capture-Western), SFPQ (Affinity Capture-Western), SFPQ (Affinity Capture-MS), SFPQ (Affinity Capture-MS), FUS (Affinity Capture-Western), SFPQ (Affinity Capture-Western), SFPQ (Affinity Capture-RNA), SFPQ (Affinity Capture-RNA), SFPQ (Reconstituted Complex), SFPQ (Affinity Capture-Western), PPARG (Two-hybrid), SFPQ (Protein-peptide), SFPQ (Affinity Capture-MS), SFPQ (Affinity Capture-MS)

ESM2 similar proteins: A7EYK3, A7SEP9, A8NYM5, A8XW44, C0NN85, C3Z1P5, C5XYW4, C5XZK6, C7YRT4, D0NHA2, D3B3B7, D5GDH4, E0VI98, E3KIY6, E3LAN7, E3X5D6, F6HQ26, O43670, P23246, P90815, Q09442, Q0P5D2, Q15427, Q16630, Q16IW3, Q1K7T5, Q1RLC9, Q298E0, Q4N6K2, Q4P2Q5, Q4UJ14, Q4WQM6, Q55A45, Q56XE4, Q5BBX9, Q5KC16, Q5NVH8, Q5R8K4, Q63627, Q6AYL5

Diamond homologs: A0A0D1C8Z4, A1A5R1, A1D4K4, A2A5N3, A2Q848, A3LXL0, A4F5G6, A5DW14, A6NFN3, A6QPR6, F1QB54, F4HT49, O04319, O43251, P04147, P0CB38, P11940, P15771, P19682, P19683, P20965, P23246, P28644, P29341, P42731, P49313, P60824, P60825, P60826, P61286, P62995, P62996, P62997, P82277, Q04836, Q08935, Q08937, Q09511, Q0CR95, Q0VD23

SIGNOR signaling

11 interactions.

A	Effect	B	Mechanism
ALK	down-regulates	SFPQ	phosphorylation
GSK3A	down-regulates	SFPQ	phosphorylation
GSK3B	down-regulates	SFPQ	phosphorylation
THRAP3	down-regulates	SFPQ	binding
PTK6	“down-regulates activity”	SFPQ	phosphorylation
SFPQ	“form complex”	NONO/SFPQ	binding
SFPQ	up-regulates	TOP1	binding
SFPQ	“form complex”	“LMX1B/SFPQ/PSPC1 complex”	binding
SFPQ	“down-regulates quantity by repression”	TH	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 192 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Processing of Capped Intron-Containing Pre-mRNA	15	9.5×	3e-08
mRNA Polyadenylation	12	8.1×	6e-06
Macroautophagy	9	8.0×	3e-04
mRNA Splicing	9	7.6×	3e-04
mRNA Splicing - Major Pathway	17	7.2×	7e-08
SARS-CoV-2-host interactions	7	6.4×	6e-03
Metabolism of RNA	16	5.1×	1e-05
SARS-CoV Infections	11	4.7×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
membraneless organelle assembly	5	33.6×	8e-05
activation of innate immune response	6	17.3×	2e-04
mRNA stabilization	6	13.2×	7e-04
negative regulation of translation	9	10.6×	8e-05
autophagosome maturation	5	10.5×	8e-03
positive regulation of translation	7	9.6×	9e-04
mRNA splicing, via spliceosome	17	9.3×	5e-09
regulation of alternative mRNA splicing, via spliceosome	6	8.8×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1464 predictions. Top by Δscore:

Variant	Effect	Δscore
1:35184726:C:CT	acceptor_gain	1.0000
1:35184727:A:AC	acceptor_gain	1.0000
1:35184727:A:C	acceptor_gain	1.0000
1:35187010:T:TA	donor_gain	1.0000
1:35187011:C:A	donor_gain	1.0000
1:35187121:ATC:A	acceptor_loss	1.0000
1:35187123:C:A	acceptor_loss	1.0000
1:35187123:C:CC	acceptor_gain	1.0000
1:35187198:CTTA:C	donor_loss	1.0000
1:35187199:TTA:T	donor_loss	1.0000
1:35187200:TACCT:T	donor_loss	1.0000
1:35187201:A:AC	donor_gain	1.0000
1:35187201:ACCT:A	donor_gain	1.0000
1:35187201:ACCTC:A	donor_gain	1.0000
1:35187202:C:CC	donor_gain	1.0000
1:35187202:CCT:C	donor_gain	1.0000
1:35187202:CCTC:C	donor_gain	1.0000
1:35187202:CCTCC:C	donor_gain	1.0000
1:35187248:CCCG:C	acceptor_gain	1.0000
1:35187249:CCG:C	acceptor_gain	1.0000
1:35187249:CCGC:C	acceptor_gain	1.0000
1:35187250:CG:C	acceptor_gain	1.0000
1:35187250:CGC:C	acceptor_gain	1.0000
1:35187250:CGCT:C	acceptor_loss	1.0000
1:35187251:GCTG:G	acceptor_loss	1.0000
1:35187252:C:CC	acceptor_gain	1.0000
1:35187252:CTGC:C	acceptor_loss	1.0000
1:35187253:T:A	acceptor_loss	1.0000
1:35187966:GACT:G	donor_loss	1.0000
1:35187967:ACT:A	donor_loss	1.0000

AlphaMissense

4592 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:35188073:C:G	R572P	1.000
1:35188076:C:G	R571P	1.000
1:35189021:C:G	R560P	1.000
1:35189022:G:T	R560S	1.000
1:35189043:G:C	H553D	1.000
1:35189045:A:G	L552P	1.000
1:35189057:C:G	R548P	1.000
1:35189058:G:T	R548S	1.000
1:35189063:A:G	L546S	1.000
1:35189072:T:G	Q543P	1.000
1:35189075:C:G	R542P	1.000
1:35189077:T:A	R541S	1.000
1:35189077:T:G	R541S	1.000
1:35189078:C:G	R541T	1.000
1:35189084:A:G	L539P	1.000
1:35189084:A:T	L539Q	1.000
1:35189188:T:G	Q537P	1.000
1:35189191:C:G	R536P	1.000
1:35189192:G:A	R536C	1.000
1:35189192:G:T	R536S	1.000
1:35189194:A:C	L535W	1.000
1:35189194:A:G	L535S	1.000
1:35189197:A:G	L534P	1.000
1:35189204:C:G	A532P	1.000
1:35189206:T:G	Q531P	1.000
1:35189209:T:G	H530P	1.000
1:35189210:G:C	H530D	1.000
1:35189215:T:G	H528P	1.000
1:35189221:G:T	A526D	1.000
1:35189222:C:G	A526P	1.000

dbSNP variants (sampled 300 via entrez): RS1000109361 (1:35181081 C>T), RS1000112358 (1:35185214 G>T), RS1000152345 (1:35183735 A>T), RS1000373238 (1:35183953 T>A,C), RS1000477142 (1:35178228 T>C), RS1000637036 (1:35189408 G>A), RS1000716472 (1:35188690 C>T), RS1000766178 (1:35178471 G>A,C), RS1000887548 (1:35177707 T>C), RS1000924647 (1:35193254 A>C,G,T), RS1000939436 (1:35177879 A>T), RS1001133145 (1:35183758 C>T), RS1001197481 (1:35178042 GAAT>G), RS1001313319 (1:35177785 A>G,T), RS1001456312 (1:35188230 A>C)

Disease associations

OMIM: gene MIM:605199 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): primary ovarian failure (MONDO:0005387)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001040_1	Endometrial cancer	6.000000e-06
GCST005038_30	Allergic disease (asthma, hay fever or eczema)	1.000000e-08
GCST008162_84	Hip circumference	9.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004230	endometrial neoplasm

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5725114 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.19	Kd	6393	nM	CHEMBL3752910
5.19	ED50	6393	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 10 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149389: Binding affinity to human SFPQ incubated for 45 mins by Kinobead based pull down assay	kd	6.3925	uM

CTD chemical–gene interactions

101 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	5
sodium arsenite	decreases reaction, decreases expression, affects cotreatment, increases abundance, affects reaction (+2 more)	4
bisphenol A	decreases expression, affects cotreatment, affects expression, increases abundance	3
Nickel	affects expression, increases expression, decreases reaction	3
Tobacco Smoke Pollution	affects expression, increases expression	3
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	2
Arsenic Trioxide	increases expression, increases response to substance	2
Arsenic	decreases expression, affects cotreatment, increases abundance	2
Caffeine	affects phosphorylation, increases expression	2
Progesterone	decreases expression, increases expression	2
Tretinoin	affects cotreatment, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases expression	1
ginger extract	affects cotreatment, affects expression, increases abundance	1
geldanamycin	increases expression	1
2,4,6-tribromophenol	decreases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
deoxynivalenol	increases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, increases expression, decreases expression	1
decabromobiphenyl ether	decreases expression	1
trichostatin A	affects expression, decreases reaction	1
arsenite	affects expression	1
methylparaben	decreases expression	1
afimoxifene	decreases expression	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
tri-o-cresyl phosphate	decreases expression	1
bleomycetin	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652431	Binding	Binding affinity to human SFPQ incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B122	UOK145	Cancer cell line	Female

Clinical trials (associated diseases)

75 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure
NCT02062931	PHASE1/PHASE2	UNKNOWN	Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure
NCT02151890	PHASE1/PHASE2	COMPLETED	Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure
NCT02372474	PHASE1/PHASE2	COMPLETED	It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure
NCT02603744	PHASE1/PHASE2	UNKNOWN	Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)
NCT02644447	PHASE1/PHASE2	COMPLETED	Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF
NCT03069209	PHASE1/PHASE2	UNKNOWN	Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)
NCT03985462	PHASE1/PHASE2	WITHDRAWN	Very Small Embryonic-like Stem Cells for Ovary
NCT04009473	PHASE1/PHASE2	UNKNOWN	Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
NCT04071574	PHASE1/PHASE2	COMPLETED	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility
NCT04922398	PHASE1/PHASE2	UNKNOWN	Ovarian Injection of PRP (Platelet -Rich Plasma) Vs Normal Saline in Premature Ovarian Insufficiency
NCT05462379	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Autologous Heterotopic Fresh Ovarian Graft in Woman With LACC Eligible for Pelvic Radiotherapy Treatment.
NCT06202547	PHASE1/PHASE2	UNKNOWN	Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
NCT01129947	EARLY_PHASE1	WITHDRAWN	The Use of DHEA in Women With Premature Ovarian Failure
NCT05522634	EARLY_PHASE1	UNKNOWN	A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency
NCT07308327	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial
NCT00001275	Not specified	COMPLETED	Ovarian Follicle Function in Patients With Primary Ovarian Failure
NCT00001306	Not specified	COMPLETED	Steroid Therapy in Autoimmune Premature Ovarian Failure
NCT00006156	Not specified	COMPLETED	Feasibility Study for Development of an Early Test for Ovarian Failure
NCT00119925	Not specified	UNKNOWN	‘SPRING’-Study: Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists